Analysts Set Axon Enterprise, Inc. (NASDAQ:AXON) Price Target at $626.45

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have received a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $640.91.

A number of analysts have commented on AXON shares. Needham & Company LLC boosted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a report on Thursday. Craig Hallum downgraded shares of Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. The Goldman Sachs Group boosted their price target on shares of Axon Enterprise from $500.00 to $700.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Barclays upped their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Northcoast Research downgraded Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $684.59 on Monday. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The firm has a fifty day simple moving average of $564.50 and a two-hundred day simple moving average of $585.83. Axon Enterprise has a 12 month low of $273.52 and a 12 month high of $715.99. The firm has a market capitalization of $53.29 billion, a PE ratio of 176.90, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm had revenue of $603.63 million during the quarter, compared to analysts’ expectations of $585.67 million. During the same period last year, the company earned $1.15 earnings per share. The business’s revenue was up 31.3% on a year-over-year basis. Analysts forecast that Axon Enterprise will post 5.8 EPS for the current fiscal year.

Insider Activity

In related news, Director Jeri Williams sold 307 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the sale, the director now directly owns 1,627 shares of the company’s stock, valued at $899,275.44. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the transaction, the chief executive officer now directly owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. This represents a 0.33% decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.40% of the company’s stock.

Institutional Trading of Axon Enterprise

Institutional investors have recently added to or reduced their stakes in the business. TCTC Holdings LLC lifted its stake in shares of Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 24 shares during the last quarter. Fourth Dimension Wealth LLC bought a new stake in Axon Enterprise in the fourth quarter valued at approximately $30,000. Bartlett & CO. Wealth Management LLC boosted its stake in shares of Axon Enterprise by 132.0% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 33 shares during the period. Catalyst Capital Advisors LLC bought a new stake in Axon Enterprise during the 1st quarter valued at $32,000. Finally, New Wave Wealth Advisors LLC purchased a new stake in Axon Enterprise during the 4th quarter valued at $40,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.